Quikening personal page - To The Moon

Quikening

Quikening

No personal profile

7Follow

11Followers

1Topic

0Badge

2025-06-23

$Coupang, Inc.(CPNG)$ No. Not good enough a stock. it will take many months to hit potential. Run while I can make a profit

2025-02-26

Is this some fake news. NVDA earnings hasn't been announced yet.

Stock Track | GraniteShares 2x Long NVDA Daily ETF Plummets 5.03% Following NVIDIA's Earnings Release

2021-08-12

$BioNTech SE(BNTX)$Can’t wait till China announcers the booster shot!

2021-08-12

$BioNTech SE(BNTX)$https://www.nytimes.com/2021/08/11/us/politics/third-vaccine-dose-approval.htmlF.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems

2021-08-12

$Novavax(NVAX)$Covid-19 pandemic: Novavax shot may get nod in India even before US

2021-08-11

$Novavax(NVAX)$The interest in Novavax increases as countries one by one, come on board to book their doses. https://www.reuters.com/world/europe/denmark-buy-novavax-vaccines-part-eu-deal-2021-08-11/

2021-08-13

$Novavax(NVAX)$WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/

2021-08-07

$Moderna, Inc.(MRNA)$Up!

2021-08-06

Lol. Who cares about fda submission when it can keep on selling whatever it produces as much as they produce?

Sorry, the original content has been removed

2021-09-23

$Novavax(NVAX)$GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI)."Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4087604108275250","uuid":"4087604108275250","gmtCreate":1624501072641,"gmtModify":1627607735090,"name":"Quikening","pinyin":"quikening","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":11,"headSize":7,"tweetSize":0,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":3,"name":"书生虎","nameTw":"書生虎","represent":"努力向上","factor":"发布10条非转发主帖,其中5条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":1,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.08.03","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.18","exceedPercentage":"93.35%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"44212b71d0be4ec88898348dbe882e03-2","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Executive Tiger","description":"The transaction amount of the securities account reaches $300,000","bigImgUrl":"https://static.tigerbbs.com/9d20b23f1b6335407f882bc5c2ad12c0","smallImgUrl":"https://static.tigerbbs.com/ada3b4533518ace8404a3f6dd192bd29","grayImgUrl":"https://static.tigerbbs.com/177f283ba21d1c077054dac07f88f3bd","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"80.33%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.06.18","exceedPercentage":"93.75%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":7,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":521724636746488,"gmtCreate":1768409307388,"gmtModify":1768409310407,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"title":"","htmlText":"<a href=\"https://ttm.financial/OPT/NBIS 20260116 90.0 PUT\">$NBIS 20260116 90.0 PUT$</a> yay","listText":"<a href=\"https://ttm.financial/OPT/NBIS 20260116 90.0 PUT\">$NBIS 20260116 90.0 PUT$</a> yay","text":"$NBIS 20260116 90.0 PUT$ yay","images":[{"img":"https://community-static.tradeup.com/news/2a1888220accec54c2da683b1d9c2b89","width":"1008","height":"1657"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/521724636746488","isVote":1,"tweetType":1,"viewCount":164,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":492764470231144,"gmtCreate":1761326384754,"gmtModify":1761326387346,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CRCL\">$Circle Internet Corp.(CRCL)$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/S/CRCL\">$Circle Internet Corp.(CRCL)$</a>&nbsp;","text":"$Circle Internet Corp.(CRCL)$","images":[{"img":"https://community-static.tradeup.com/news/e3004b285c0da0afdcc72d4d22e2190c","width":"1008","height":"1657"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/492764470231144","isVote":1,"tweetType":1,"viewCount":825,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":492751055463336,"gmtCreate":1761323188589,"gmtModify":1761323191029,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/OPT/NBIS 20260116 90.0 PUT\">$NBIS 20260116 90.0 PUT$</a>&nbsp;","listText":"<a href=\"https://ttm.financial/OPT/NBIS 20260116 90.0 PUT\">$NBIS 20260116 90.0 PUT$</a>&nbsp;","text":"$NBIS 20260116 90.0 PUT$","images":[{"img":"https://community-static.tradeup.com/news/f79e6685ef2b9bb45b29e81b161f08e0","width":"1008","height":"1657"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/492751055463336","isVote":1,"tweetType":1,"viewCount":615,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":466644673970688,"gmtCreate":1754964580451,"gmtModify":1754964583321,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"$203","listText":"$203","text":"$203","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/466644673970688","isVote":1,"tweetType":1,"viewCount":1008,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":449008837423616,"gmtCreate":1750647632198,"gmtModify":1750648296910,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CPNG\">$Coupang, Inc.(CPNG)$&nbsp;</a><v-v data-views=\"0\"></v-v> No. Not good enough a stock. it will take many months to hit potential. Run while I can make a profit","listText":"<a href=\"https://ttm.financial/S/CPNG\">$Coupang, Inc.(CPNG)$&nbsp;</a><v-v data-views=\"0\"></v-v> No. Not good enough a stock. it will take many months to hit potential. Run while I can make a profit","text":"$Coupang, Inc.(CPNG)$ No. Not good enough a stock. it will take many months to hit potential. Run while I can make a profit","images":[{"img":"https://community-static.tradeup.com/news/d2035e36346b4249e7d0760386a0d172","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":68,"commentSize":3,"repostSize":63,"link":"https://ttm.financial/post/449008837423616","isVote":1,"tweetType":1,"viewCount":3137,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010968","authorId":"10000000000010968","name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"10000000000010968","idStr":"10000000000010968"},"content":"Congratulations on your recent gains! Your dedication to value investing is clearly paying off. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳🥳 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","text":"Congratulations on your recent gains! Your dedication to value investing is clearly paying off. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳🥳 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","html":"Congratulations on your recent gains! Your dedication to value investing is clearly paying off. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳🥳 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":407792759390384,"gmtCreate":1740581713430,"gmtModify":1740581717982,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"Is this some fake news. NVDA earnings hasn't been announced yet.&nbsp;","listText":"Is this some fake news. NVDA earnings hasn't been announced yet.&nbsp;","text":"Is this some fake news. NVDA earnings hasn't been announced yet.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/407792759390384","repostId":"1125447418","repostType":2,"repost":{"id":"1125447418","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1740495218,"share":"https://ttm.financial/m/news/1125447418?lang=en_US&edition=fundamental","pubTime":"2025-02-25 22:53","market":"us","language":"en","title":"Stock Track | GraniteShares 2x Long NVDA Daily ETF Plummets 5.03% Following NVIDIA's Earnings Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1125447418","media":"Stock Track","summary":"The GraniteShares 2x Long NVDA Daily ETF  tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.NVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA ","content":"<p>The GraniteShares 2x Long NVDA Daily ETF (NVDL) tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.</p>\n\n<p>NVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA shares ahead of the earnings release, betting on its long-term prospects in the AI revolution.</p>\n\n<p>While NVIDIA's earnings and revenue figures were strong, beating analyst estimates, the market's reaction to the report appears to have impacted the leveraged ETF NVDL. Traders had anticipated significant volatility in NVIDIA's stock following the earnings announcement, and the amplified movement in NVDL reflects this expectation.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GraniteShares 2x Long NVDA Daily ETF Plummets 5.03% Following NVIDIA's Earnings Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GraniteShares 2x Long NVDA Daily ETF Plummets 5.03% Following NVIDIA's Earnings Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The GraniteShares 2x Long NVDA Daily ETF (NVDL) tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.</p>\n\n<p>NVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA shares ahead of the earnings release, betting on its long-term prospects in the AI revolution.</p>\n\n<p>While NVIDIA's earnings and revenue figures were strong, beating analyst estimates, the market's reaction to the report appears to have impacted the leveraged ETF NVDL. Traders had anticipated significant volatility in NVIDIA's stock following the earnings announcement, and the amplified movement in NVDL reflects this expectation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDL":"2倍做多NVDA ETF-GraniteShares"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125447418","content_text":"The GraniteShares 2x Long NVDA Daily ETF (NVDL) tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.\nNVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA shares ahead of the earnings release, betting on its long-term prospects in the AI revolution.\nWhile NVIDIA's earnings and revenue figures were strong, beating analyst estimates, the market's reaction to the report appears to have impacted the leveraged ETF NVDL. Traders had anticipated significant volatility in NVIDIA's stock following the earnings announcement, and the amplified movement in NVDL reflects this expectation.","news_type":1,"symbols_score_info":{"NVDL":1}},"isVote":1,"tweetType":1,"viewCount":2517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863504611,"gmtCreate":1632404416833,"gmtModify":1676530773890,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera","text":"$Novavax(NVAX)$GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863504611","isVote":1,"tweetType":1,"viewCount":2479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":882554794,"gmtCreate":1631710914418,"gmtModify":1676530614770,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>https://www.fool.com/investing/2021/09/15/is-novavax-a-buy/?source=eptyholnk0000202&amp;utm_source=yahoo-host&amp;utm_medium=feed&amp;utm_campaign=article&amp;yptr=yahooNice!","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>https://www.fool.com/investing/2021/09/15/is-novavax-a-buy/?source=eptyholnk0000202&amp;utm_source=yahoo-host&amp;utm_medium=feed&amp;utm_campaign=article&amp;yptr=yahooNice!","text":"$Novavax(NVAX)$https://www.fool.com/investing/2021/09/15/is-novavax-a-buy/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article&yptr=yahooNice!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/882554794","isVote":1,"tweetType":1,"viewCount":2539,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":889541237,"gmtCreate":1631162390829,"gmtModify":1676530484254,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Do y’all think it will fall a little? To what price? So that I can accumulate!!!!","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Do y’all think it will fall a little? To what price? So that I can accumulate!!!!","text":"$Novavax(NVAX)$Do y’all think it will fall a little? To what price? So that I can accumulate!!!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/889541237","isVote":1,"tweetType":1,"viewCount":2281,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":837853984,"gmtCreate":1629876998848,"gmtModify":1676530159540,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>In the U.K., novavax, which is not even approved yet, is going to be in a booster study&nbsp;https://www.gov.uk/government/news/new-study-to-test-third-covid-19-vaccine-for-people-with-weakened-immune-systems","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>In the U.K., novavax, which is not even approved yet, is going to be in a booster study&nbsp;https://www.gov.uk/government/news/new-study-to-test-third-covid-19-vaccine-for-people-with-weakened-immune-systems","text":"$Novavax(NVAX)$In the U.K., novavax, which is not even approved yet, is going to be in a booster study https://www.gov.uk/government/news/new-study-to-test-third-covid-19-vaccine-for-people-with-weakened-immune-systems","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/837853984","isVote":1,"tweetType":1,"viewCount":2381,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":839121809,"gmtCreate":1629127918601,"gmtModify":1676529941099,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"Accumulate and average down?","listText":"Accumulate and average down?","text":"Accumulate and average down?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839121809","repostId":"839189151","repostType":1,"repost":{"id":839189151,"gmtCreate":1629126570073,"gmtModify":1676529940538,"author":{"id":"3577314357018428","authorId":"3577314357018428","name":"Jamesnyh","avatar":"https://static.tigerbbs.com/47af6b20358b45f985ca76d42f247c9c","crmLevel":12,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3577314357018428","idStr":"3577314357018428"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Who can help me???&nbsp;","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Who can help me???&nbsp;","text":"$BioNTech SE(BNTX)$Who can help me???","images":[{"img":"https://static.tigerbbs.com/1a93b0fdbf7ebfbe684613f3da1f4ee2","width":"1242","height":"2151"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/839189151","isVote":1,"tweetType":1,"viewCount":0,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},"isVote":1,"tweetType":1,"viewCount":2024,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894486143,"gmtCreate":1628847901782,"gmtModify":1676529873746,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&amp;D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&amp;D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/","text":"$Novavax(NVAX)$WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894486143","isVote":1,"tweetType":1,"viewCount":2123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894284119,"gmtCreate":1628829750531,"gmtModify":1676529868359,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>&nbsp;FDA permits Covid vaccine booster shots for people with weakened immune systemsKEY POINTSThe FDA authorized Covid vaccine booster shots for people with weakened immune systems.Such people – including cancer and HIV patients – in general do not produce an adequate immune response after receiving two doses of a vaccine, U.S. officials say.The agency's move may shield some of the most vulnerable Americans from the highly contagious delta variant.https://www.cnbc.com/2021/08/13/covid-booster-shots-fda-permits-third-dose-for-the-immune-deficient.html","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>&nbsp;FDA permits Covid vaccine booster shots for people with weakened immune systemsKEY POINTSThe FDA authorized Covid vaccine booster shots for people with weakened immune systems.Such people – including cancer and HIV patients – in general do not produce an adequate immune response after receiving two doses of a vaccine, U.S. officials say.The agency's move may shield some of the most vulnerable Americans from the highly contagious delta variant.https://www.cnbc.com/2021/08/13/covid-booster-shots-fda-permits-third-dose-for-the-immune-deficient.html","text":"$BioNTech SE(BNTX)$ FDA permits Covid vaccine booster shots for people with weakened immune systemsKEY POINTSThe FDA authorized Covid vaccine booster shots for people with weakened immune systems.Such people – including cancer and HIV patients – in general do not produce an adequate immune response after receiving two doses of a vaccine, U.S. officials say.The agency's move may shield some of the most vulnerable Americans from the highly contagious delta variant.https://www.cnbc.com/2021/08/13/covid-booster-shots-fda-permits-third-dose-for-the-immune-deficient.html","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894284119","isVote":1,"tweetType":1,"viewCount":1709,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894646606,"gmtCreate":1628824559105,"gmtModify":1676529866790,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Update From FUJIFILM Diosynth Biotechnologies And Novavax About Their Pandemic Vaccine CandidateThe corporate office of FUJIFILM Diosynth Biotechnologies (FDB) sent WTAW News an update on the development of a pandemic vaccine candidate with Novavax.What FDB describes as “additional required analytical work” is underway.Both companies expect to submit the vaccine candidate for emergency use authorization in the United States sometime between October 1 and the end of this year.The update also says the companies are collaborating to advance commercial manufacturing that involves restarting manufacturing at FDB’s facility in the Bryan/College Station biocorridor.According to the news release, their vaccine candidate has demonstrated a robu","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Update From FUJIFILM Diosynth Biotechnologies And Novavax About Their Pandemic Vaccine CandidateThe corporate office of FUJIFILM Diosynth Biotechnologies (FDB) sent WTAW News an update on the development of a pandemic vaccine candidate with Novavax.What FDB describes as “additional required analytical work” is underway.Both companies expect to submit the vaccine candidate for emergency use authorization in the United States sometime between October 1 and the end of this year.The update also says the companies are collaborating to advance commercial manufacturing that involves restarting manufacturing at FDB’s facility in the Bryan/College Station biocorridor.According to the news release, their vaccine candidate has demonstrated a robu","text":"$Novavax(NVAX)$Update From FUJIFILM Diosynth Biotechnologies And Novavax About Their Pandemic Vaccine CandidateThe corporate office of FUJIFILM Diosynth Biotechnologies (FDB) sent WTAW News an update on the development of a pandemic vaccine candidate with Novavax.What FDB describes as “additional required analytical work” is underway.Both companies expect to submit the vaccine candidate for emergency use authorization in the United States sometime between October 1 and the end of this year.The update also says the companies are collaborating to advance commercial manufacturing that involves restarting manufacturing at FDB’s facility in the Bryan/College Station biocorridor.According to the news release, their vaccine candidate has demonstrated a robu","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894646606","isVote":1,"tweetType":1,"viewCount":1936,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894840591,"gmtCreate":1628818244613,"gmtModify":1676529864162,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Waiting for ID IN PH EUA!!!!","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Waiting for ID IN PH EUA!!!!","text":"$Novavax(NVAX)$Waiting for ID IN PH EUA!!!!","images":[{"img":"https://static.tigerbbs.com/e09cc1188bbe5dfb8a26793d1c7c9d5c","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894840591","isVote":1,"tweetType":1,"viewCount":1100,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":895565780,"gmtCreate":1628757551540,"gmtModify":1676529844505,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid-19 pandemic: Novavax shot may get nod in India even before US","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid-19 pandemic: Novavax shot may get nod in India even before US","text":"$Novavax(NVAX)$Covid-19 pandemic: Novavax shot may get nod in India even before US","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/895565780","isVote":1,"tweetType":1,"viewCount":2018,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3586655655659820","authorId":"3586655655659820","name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3586655655659820","idStr":"3586655655659820"},"content":"Philippines too","text":"Philippines too","html":"Philippines too"},{"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"content":"https://www.business-standard.com/article/current-affairs/covid-19-pandemic-novavax-shot-may-get-nod-in-india-even-before-us-121081100024_1.html","text":"https://www.business-standard.com/article/current-affairs/covid-19-pandemic-novavax-shot-may-get-nod-in-india-even-before-us-121081100024_1.html","html":"https://www.business-standard.com/article/current-affairs/covid-19-pandemic-novavax-shot-may-get-nod-in-india-even-before-us-121081100024_1.html"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895261151,"gmtCreate":1628748227273,"gmtModify":1676529841506,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>https://www.nytimes.com/2021/08/11/us/politics/third-vaccine-dose-approval.htmlF.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>https://www.nytimes.com/2021/08/11/us/politics/third-vaccine-dose-approval.htmlF.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems","text":"$BioNTech SE(BNTX)$https://www.nytimes.com/2021/08/11/us/politics/third-vaccine-dose-approval.htmlF.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/895261151","isVote":1,"tweetType":1,"viewCount":1413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895902583,"gmtCreate":1628698661442,"gmtModify":1676529826760,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Can’t wait till China announcers the booster shot!","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Can’t wait till China announcers the booster shot!","text":"$BioNTech SE(BNTX)$Can’t wait till China announcers the booster shot!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/895902583","isVote":1,"tweetType":1,"viewCount":1536,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3552187859584454","authorId":"3552187859584454","name":"宁可十年不将军","avatar":"https://static.tigerbbs.com/847e8bf5fbdde42dbf452eb3e06f39b8","crmLevel":1,"crmLevelSwitch":0,"authorIdStr":"3552187859584454","idStr":"3552187859584454"},"content":"Then announce it quickly","text":"Then announce it quickly","html":"Then announce it quickly"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895063037,"gmtCreate":1628694969529,"gmtModify":1676529825188,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>The interest in Novavax increases as countries one by one, come on board to book their doses.&nbsp;https://www.reuters.com/world/europe/denmark-buy-novavax-vaccines-part-eu-deal-2021-08-11/","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>The interest in Novavax increases as countries one by one, come on board to book their doses.&nbsp;https://www.reuters.com/world/europe/denmark-buy-novavax-vaccines-part-eu-deal-2021-08-11/","text":"$Novavax(NVAX)$The interest in Novavax increases as countries one by one, come on board to book their doses. https://www.reuters.com/world/europe/denmark-buy-novavax-vaccines-part-eu-deal-2021-08-11/","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/895063037","isVote":1,"tweetType":1,"viewCount":2037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":896849830,"gmtCreate":1628571618920,"gmtModify":1703508340264,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4087604108275250","idStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Please continue to go up to 260 again!","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Please continue to go up to 260 again!","text":"$Novavax(NVAX)$Please continue to go up to 260 again!","images":[{"img":"https://static.tigerbbs.com/6324665344ff8894b76fddbfeff8d5bb","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/896849830","isVote":1,"tweetType":1,"viewCount":1205,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":449008837423616,"gmtCreate":1750647632198,"gmtModify":1750648296910,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/CPNG\">$Coupang, Inc.(CPNG)$&nbsp;</a><v-v data-views=\"0\"></v-v> No. Not good enough a stock. it will take many months to hit potential. Run while I can make a profit","listText":"<a href=\"https://ttm.financial/S/CPNG\">$Coupang, Inc.(CPNG)$&nbsp;</a><v-v data-views=\"0\"></v-v> No. Not good enough a stock. it will take many months to hit potential. Run while I can make a profit","text":"$Coupang, Inc.(CPNG)$ No. Not good enough a stock. it will take many months to hit potential. Run while I can make a profit","images":[{"img":"https://community-static.tradeup.com/news/d2035e36346b4249e7d0760386a0d172","width":"981","height":"1637"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":68,"commentSize":3,"repostSize":63,"link":"https://ttm.financial/post/449008837423616","isVote":1,"tweetType":1,"viewCount":3137,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"10000000000010968","authorId":"10000000000010968","name":"Tiger_CashBoostAccount","avatar":"https://community-static.tradeup.com/news/ae2d4002ef9664aba005cb3020f416f5","crmLevel":1,"crmLevelSwitch":0,"idStr":"10000000000010968","authorIdStr":"10000000000010968"},"content":"Congratulations on your recent gains! Your dedication to value investing is clearly paying off. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳🥳 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","text":"Congratulations on your recent gains! Your dedication to value investing is clearly paying off. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳🥳 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website.","html":"Congratulations on your recent gains! Your dedication to value investing is clearly paying off. Trade with Tiger Cash Boost Account and use contra trading to enhance your strategies.🥳🥳 Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here. Other helpful links: How to open a CBA. How to link your CDP account. Other FAQs on CBA. Cash Boost Account Website."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":407792759390384,"gmtCreate":1740581713430,"gmtModify":1740581717982,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"Is this some fake news. NVDA earnings hasn't been announced yet.&nbsp;","listText":"Is this some fake news. NVDA earnings hasn't been announced yet.&nbsp;","text":"Is this some fake news. NVDA earnings hasn't been announced yet.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/407792759390384","repostId":"1125447418","repostType":2,"repost":{"id":"1125447418","kind":"news","weMediaInfo":{"introduction":"Track stock‘s movements and relevant news","home_visible":1,"media_name":"Stock Track","id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"pubTimestamp":1740495218,"share":"https://ttm.financial/m/news/1125447418?lang=en_US&edition=fundamental","pubTime":"2025-02-25 22:53","market":"us","language":"en","title":"Stock Track | GraniteShares 2x Long NVDA Daily ETF Plummets 5.03% Following NVIDIA's Earnings Release","url":"https://stock-news.laohu8.com/highlight/detail?id=1125447418","media":"Stock Track","summary":"The GraniteShares 2x Long NVDA Daily ETF  tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.NVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA ","content":"<p>The GraniteShares 2x Long NVDA Daily ETF (NVDL) tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.</p>\n\n<p>NVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA shares ahead of the earnings release, betting on its long-term prospects in the AI revolution.</p>\n\n<p>While NVIDIA's earnings and revenue figures were strong, beating analyst estimates, the market's reaction to the report appears to have impacted the leveraged ETF NVDL. Traders had anticipated significant volatility in NVIDIA's stock following the earnings announcement, and the amplified movement in NVDL reflects this expectation.</p>","source":"ai_movement_en","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | GraniteShares 2x Long NVDA Daily ETF Plummets 5.03% Following NVIDIA's Earnings Release</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | GraniteShares 2x Long NVDA Daily ETF Plummets 5.03% Following NVIDIA's Earnings Release\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-25 22:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>The GraniteShares 2x Long NVDA Daily ETF (NVDL) tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.</p>\n\n<p>NVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA shares ahead of the earnings release, betting on its long-term prospects in the AI revolution.</p>\n\n<p>While NVIDIA's earnings and revenue figures were strong, beating analyst estimates, the market's reaction to the report appears to have impacted the leveraged ETF NVDL. Traders had anticipated significant volatility in NVIDIA's stock following the earnings announcement, and the amplified movement in NVDL reflects this expectation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVDL":"2倍做多NVDA ETF-GraniteShares"},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125447418","content_text":"The GraniteShares 2x Long NVDA Daily ETF (NVDL) tumbled 5.03% on Tuesday, underperforming the broader market. This plummet came in the wake of NVIDIA's highly anticipated earnings report, which was released after the market close on Wednesday, February 22nd.\nNVIDIA, the underlying stock that NVDL tracks with 2x leverage, had a rocky start to the year due to concerns over competition from Chinese AI firm DeepSeek. However, individual investors remained bullish on the stock, pouring billions into NVIDIA shares ahead of the earnings release, betting on its long-term prospects in the AI revolution.\nWhile NVIDIA's earnings and revenue figures were strong, beating analyst estimates, the market's reaction to the report appears to have impacted the leveraged ETF NVDL. Traders had anticipated significant volatility in NVIDIA's stock following the earnings announcement, and the amplified movement in NVDL reflects this expectation.","news_type":1,"symbols_score_info":{"NVDL":1}},"isVote":1,"tweetType":1,"viewCount":2517,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895902583,"gmtCreate":1628698661442,"gmtModify":1676529826760,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Can’t wait till China announcers the booster shot!","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>Can’t wait till China announcers the booster shot!","text":"$BioNTech SE(BNTX)$Can’t wait till China announcers the booster shot!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/895902583","isVote":1,"tweetType":1,"viewCount":1536,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3552187859584454","authorId":"3552187859584454","name":"宁可十年不将军","avatar":"https://static.tigerbbs.com/847e8bf5fbdde42dbf452eb3e06f39b8","crmLevel":1,"crmLevelSwitch":0,"idStr":"3552187859584454","authorIdStr":"3552187859584454"},"content":"Then announce it quickly","text":"Then announce it quickly","html":"Then announce it quickly"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895261151,"gmtCreate":1628748227273,"gmtModify":1676529841506,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>https://www.nytimes.com/2021/08/11/us/politics/third-vaccine-dose-approval.htmlF.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems","listText":"<a href=\"https://laohu8.com/S/BNTX\">$BioNTech SE(BNTX)$</a>https://www.nytimes.com/2021/08/11/us/politics/third-vaccine-dose-approval.htmlF.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems","text":"$BioNTech SE(BNTX)$https://www.nytimes.com/2021/08/11/us/politics/third-vaccine-dose-approval.htmlF.D.A. to Authorize Third Vaccine Dose for People With Weak Immune Systems","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/895261151","isVote":1,"tweetType":1,"viewCount":1413,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895565780,"gmtCreate":1628757551540,"gmtModify":1676529844505,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid-19 pandemic: Novavax shot may get nod in India even before US","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>Covid-19 pandemic: Novavax shot may get nod in India even before US","text":"$Novavax(NVAX)$Covid-19 pandemic: Novavax shot may get nod in India even before US","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/895565780","isVote":1,"tweetType":1,"viewCount":2018,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3586655655659820","authorId":"3586655655659820","name":"sunshine138","avatar":"https://static.tigerbbs.com/23149c63a63bfeec1572cc27e1322750","crmLevel":12,"crmLevelSwitch":0,"idStr":"3586655655659820","authorIdStr":"3586655655659820"},"content":"Philippines too","text":"Philippines too","html":"Philippines too"},{"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"content":"https://www.business-standard.com/article/current-affairs/covid-19-pandemic-novavax-shot-may-get-nod-in-india-even-before-us-121081100024_1.html","text":"https://www.business-standard.com/article/current-affairs/covid-19-pandemic-novavax-shot-may-get-nod-in-india-even-before-us-121081100024_1.html","html":"https://www.business-standard.com/article/current-affairs/covid-19-pandemic-novavax-shot-may-get-nod-in-india-even-before-us-121081100024_1.html"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":895063037,"gmtCreate":1628694969529,"gmtModify":1676529825188,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>The interest in Novavax increases as countries one by one, come on board to book their doses.&nbsp;https://www.reuters.com/world/europe/denmark-buy-novavax-vaccines-part-eu-deal-2021-08-11/","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>The interest in Novavax increases as countries one by one, come on board to book their doses.&nbsp;https://www.reuters.com/world/europe/denmark-buy-novavax-vaccines-part-eu-deal-2021-08-11/","text":"$Novavax(NVAX)$The interest in Novavax increases as countries one by one, come on board to book their doses. https://www.reuters.com/world/europe/denmark-buy-novavax-vaccines-part-eu-deal-2021-08-11/","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/895063037","isVote":1,"tweetType":1,"viewCount":2037,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894486143,"gmtCreate":1628847901782,"gmtModify":1676529873746,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&amp;D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&amp;D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/","text":"$Novavax(NVAX)$WHO webinar starts August 13 13:00 CET:WHO consultation on COVID-19 vaccines research – 13 August 202113 August 2021 13:00 – 18:00 CETIn continuation to the scientific discussions on COVID-19 vaccines research, WHO R&D Blueprint is organizing a consultation on the state of the art and best research methods to evaluate existing, modified and new COVID-19 vaccines.The objectives of this forthcoming consultation will be to review the available evidence on the efficacy and effectiveness of vaccines being deployed in terms of:Emerging variants effect on protection levels Duration of protectionSafety of booster vaccinesResearch to evaluate various delivery strategieshttps://www.who.int/news-room/events/detail/2021/08/13/default-calendar/","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894486143","isVote":1,"tweetType":1,"viewCount":2123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":893506822,"gmtCreate":1628272747966,"gmtModify":1703504402054,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Up!","listText":"<a href=\"https://laohu8.com/S/MRNA\">$Moderna, Inc.(MRNA)$</a>Up!","text":"$Moderna, Inc.(MRNA)$Up!","images":[{"img":"https://static.tigerbbs.com/84756344fe6174723e9fca1bc1616696","width":"1125","height":"1949"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893506822","isVote":1,"tweetType":1,"viewCount":794,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":893125431,"gmtCreate":1628248703323,"gmtModify":1703503920858,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"Lol. Who cares about fda submission when it can keep on selling whatever it produces as much as they produce?","listText":"Lol. Who cares about fda submission when it can keep on selling whatever it produces as much as they produce?","text":"Lol. Who cares about fda submission when it can keep on selling whatever it produces as much as they produce?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/893125431","repostId":"1103242546","repostType":4,"isVote":1,"tweetType":1,"viewCount":688,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":863504611,"gmtCreate":1632404416833,"gmtModify":1676530773890,"author":{"id":"4087604108275250","authorId":"4087604108275250","name":"Quikening","avatar":"https://static.tigerbbs.com/92d8e19006c39a6fb49b8ad39ebccafa","crmLevel":7,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4087604108275250","authorIdStr":"4087604108275250"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera","listText":"<a href=\"https://laohu8.com/S/NVAX\">$Novavax(NVAX)$</a>GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera","text":"$Novavax(NVAX)$GAITHERSBURG, Md., Sept. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, with its partner, Serum Institute of India Pvt. Ltd. (SII), today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-MTM adjuvant. The submission to WHO is based on the companies' previous regulatory submission to the Drugs Controller General of India (DCGI).\"Today's submission of our protein-based COVID-19 vaccine to WHO for emergency use listing is a significant step on the path to accelera","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/863504611","isVote":1,"tweetType":1,"viewCount":2479,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}